The Experts below are selected from a list of 210375 Experts worldwide ranked by ideXlab platform
D D Pierroz - One of the best experts on this subject based on the ideXlab platform.
-
revised global consensus statement on menopausal hormone therapy
Maturitas, 2016Co-Authors: T J De Villiers, Jo Ann V Pinkerton, Janet E Hall, Cerdas S Perez, Margaret Rees, C Yang, D D PierrozAbstract:The following Consensus Statement is endorsed by The International Menopause Society, The North American Menopause Society, The Endocrine Society, The European Menopause and Andropause Society, The Asia Pacific Menopause Federation, The International Osteoporosis Foundation and The Federation of Latin American Menopause Societies.
-
revised global consensus statement on menopausal hormone therapy
Climacteric, 2016Co-Authors: T J De Villiers, Jo Ann V Pinkerton, Janet E Hall, Cerdas S Perez, Margaret Rees, C Yang, D D PierrozAbstract:The following Consensus Statement is endorsed by The International Menopause Society, The North American Menopause Society, The Endocrine Society, The European Menopause and Andropause Society, The...
-
global consensus statement on menopausal hormone therapy
Climacteric, 2013Co-Authors: T J De Villiers, Janet E Hall, D D Pierroz, Margery Gass, Christopher J Haines, Roger A Lobo, Margaret ReesAbstract:The following Consensus Statement is endorsed by The American Society for Reproductive Medicine, The Asia Pacific Menopause Federation, The Endocrine Society, The European Menopause and Andropause Society, The International Menopause Society, The International Osteoporosis Foundation and The North American Menopause Society.
Margaret Rees - One of the best experts on this subject based on the ideXlab platform.
-
revised global consensus statement on menopausal hormone therapy
Maturitas, 2016Co-Authors: T J De Villiers, Jo Ann V Pinkerton, Janet E Hall, Cerdas S Perez, Margaret Rees, C Yang, D D PierrozAbstract:The following Consensus Statement is endorsed by The International Menopause Society, The North American Menopause Society, The Endocrine Society, The European Menopause and Andropause Society, The Asia Pacific Menopause Federation, The International Osteoporosis Foundation and The Federation of Latin American Menopause Societies.
-
revised global consensus statement on menopausal hormone therapy
Climacteric, 2016Co-Authors: T J De Villiers, Jo Ann V Pinkerton, Janet E Hall, Cerdas S Perez, Margaret Rees, C Yang, D D PierrozAbstract:The following Consensus Statement is endorsed by The International Menopause Society, The North American Menopause Society, The Endocrine Society, The European Menopause and Andropause Society, The...
-
Menopause
Nature Reviews Disease Primers, 2015Co-Authors: Susan R. Davis, Margaret Rees, Irene Lambrinoudaki, Maryann Lumsden, Gita D. Mishra, Lubna Pal, Nanette Santoro, Tommaso SimonciniAbstract:Menopause is an inevitable component of ageing and encompasses the loss of ovarian reproductive function, either occurring spontaneously or secondary to other conditions. It is not yet possible to accurately predict the onset of Menopause, especially early Menopause, to give women improved control of their fertility. The decline in ovarian oestrogen production at Menopause can cause physical symptoms that may be debilitating, including hot flushes and night sweats, urogenital atrophy, sexual dysfunction, mood changes, bone loss, and metabolic changes that predispose to cardiovascular disease and diabetes. The individual experience of the Menopause transition varies widely. Important influential factors include the age at which Menopause occurs, personal health and wellbeing, and each woman's environment and culture. Management options range from lifestyle assessment and intervention through to hormonal and non-hormonal pharmacotherapy, each of which has specific benefits and risks. Decisions about therapy for perimenopausal and postmenopausal women depend on symptomatology, health status, immediate and long-term health risks, personal life expectations, and the availability and cost of therapies. More effective and safe therapies for the management of menopausal symptoms need to be developed, particularly for women who have absolute contraindications to hormone therapy. For an illustrated summary of this Primer, visit: http://go.nature.com/BjvJVX Menopause is the age-related loss of female reproductive function. Here, Davis et al . describe Menopause physiology and its impact on women's health. They call for more research to understand the basic biology underlying this transition and to develop new therapies.
-
global consensus statement on menopausal hormone therapy
Climacteric, 2013Co-Authors: T J De Villiers, Janet E Hall, D D Pierroz, Margery Gass, Christopher J Haines, Roger A Lobo, Margaret ReesAbstract:The following Consensus Statement is endorsed by The American Society for Reproductive Medicine, The Asia Pacific Menopause Federation, The Endocrine Society, The European Menopause and Andropause Society, The International Menopause Society, The International Osteoporosis Foundation and The North American Menopause Society.
T J De Villiers - One of the best experts on this subject based on the ideXlab platform.
-
revised global consensus statement on menopausal hormone therapy
Maturitas, 2016Co-Authors: T J De Villiers, Jo Ann V Pinkerton, Janet E Hall, Cerdas S Perez, Margaret Rees, C Yang, D D PierrozAbstract:The following Consensus Statement is endorsed by The International Menopause Society, The North American Menopause Society, The Endocrine Society, The European Menopause and Andropause Society, The Asia Pacific Menopause Federation, The International Osteoporosis Foundation and The Federation of Latin American Menopause Societies.
-
revised global consensus statement on menopausal hormone therapy
Climacteric, 2016Co-Authors: T J De Villiers, Jo Ann V Pinkerton, Janet E Hall, Cerdas S Perez, Margaret Rees, C Yang, D D PierrozAbstract:The following Consensus Statement is endorsed by The International Menopause Society, The North American Menopause Society, The Endocrine Society, The European Menopause and Andropause Society, The...
-
global consensus statement on menopausal hormone therapy
Climacteric, 2013Co-Authors: T J De Villiers, Janet E Hall, D D Pierroz, Margery Gass, Christopher J Haines, Roger A Lobo, Margaret ReesAbstract:The following Consensus Statement is endorsed by The American Society for Reproductive Medicine, The Asia Pacific Menopause Federation, The Endocrine Society, The European Menopause and Andropause Society, The International Menopause Society, The International Osteoporosis Foundation and The North American Menopause Society.
Jo Ann V Pinkerton - One of the best experts on this subject based on the ideXlab platform.
-
the 2017 hormone therapy position statement of the north american Menopause society
Menopause, 2017Co-Authors: Jo Ann V Pinkerton, Fernando Sanchez Aguirre, Jennifer Blake, Felicia Cosman, Howard N Hodis, Susan Hoffstetter, Andrew M Kaunitz, Sheryl A Kingsberg, Pauline M Maki, Joann E MansonAbstract:The 2017 Hormone Therapy Position Statement of The North American Menopause Society (NAMS) updates the 2012 Hormone Therapy Position Statement of The North American Menopause Society and identifies future research needs. An Advisory Panel of clinicians and researchers expert in the field of women's health and Menopause was recruited by NAMS to review the 2012 Position Statement, evaluate new literature, assess the evidence, and reach consensus on recommendations, using the level of evidence to identify the strength of recommendations and the quality of the evidence. The Panel's recommendations were reviewed and approved by the NAMS Board of Trustees. Hormone therapy (HT) remains the most effective treatment for vasomotor symptoms (VMS) and the genitourinary syndrome of Menopause (GSM) and has been shown to prevent bone loss and fracture. The risks of HT differ depending on type, dose, duration of use, route of administration, timing of initiation, and whether a progestogen is used. Treatment should be individualized to identify the most appropriate HT type, dose, formulation, route of administration, and duration of use, using the best available evidence to maximize benefits and minimize risks, with periodic reevaluation of the benefits and risks of continuing or discontinuing HT. For women aged younger than 60 years or who are within 10 years of Menopause onset and have no contraindications, the benefit-risk ratio is most favorable for treatment of bothersome VMS and for those at elevated risk for bone loss or fracture. For women who initiate HT more than 10 or 20 years from Menopause onset or are aged 60 years or older, the benefit-risk ratio appears less favorable because of the greater absolute risks of coronary heart disease, stroke, venous thromboembolism, and dementia. Longer durations of therapy should be for documented indications such as persistent VMS or bone loss, with shared decision making and periodic reevaluation. For bothersome GSM symptoms not relieved with over-the-counter therapies and without indications for use of systemic HT, low-dose vaginal estrogen therapy or other therapies are recommended. This NAMS position statement has been endorsed by Academy of Women's Health, American Association of Clinical Endocrinologists, American Association of Nurse Practitioners, American Medical Women's Association, American Society for Reproductive Medicine, Asociacion Mexicana para el Estudio del Climaterio, Association of Reproductive Health Professionals, Australasian Menopause Society, Chinese Menopause Society, Colegio Mexicano de Especialistas en Ginecologia y Obstetricia, Czech Menopause and Andropause Society, Dominican Menopause Society, European Menopause and Andropause Society, German Menopause Society, Groupe d’etudes de la Menopause et du vieillissement Hormonal, HealthyWomen, Indian Menopause Society, International Menopause Society, International Osteoporosis Foundation, International Society for the Study of Women's Sexual Health, Israeli Menopause Society, Japan Society of Menopause and Women's Health, Korean Society of Menopause, Menopause Research Society of Singapore, National Association of Nurse Practitioners in Women's Health, SOBRAC and FEBRASGO, SIGMA Canadian Menopause Society, Societa Italiana della Menopausa, Society of Obstetricians and Gynaecologists of Canada, South African Menopause Society, Taiwanese Menopause Society, and the Thai Menopause Society. The American College of Obstetricians and Gynecologists supports the value of this clinical document as an educational tool, June 2017. The British Menopause Society supports this Position Statement.
-
revised global consensus statement on menopausal hormone therapy
Maturitas, 2016Co-Authors: T J De Villiers, Jo Ann V Pinkerton, Janet E Hall, Cerdas S Perez, Margaret Rees, C Yang, D D PierrozAbstract:The following Consensus Statement is endorsed by The International Menopause Society, The North American Menopause Society, The Endocrine Society, The European Menopause and Andropause Society, The Asia Pacific Menopause Federation, The International Osteoporosis Foundation and The Federation of Latin American Menopause Societies.
-
revised global consensus statement on menopausal hormone therapy
Climacteric, 2016Co-Authors: T J De Villiers, Jo Ann V Pinkerton, Janet E Hall, Cerdas S Perez, Margaret Rees, C Yang, D D PierrozAbstract:The following Consensus Statement is endorsed by The International Menopause Society, The North American Menopause Society, The Endocrine Society, The European Menopause and Andropause Society, The...
Janet E Hall - One of the best experts on this subject based on the ideXlab platform.
-
revised global consensus statement on menopausal hormone therapy
Maturitas, 2016Co-Authors: T J De Villiers, Jo Ann V Pinkerton, Janet E Hall, Cerdas S Perez, Margaret Rees, C Yang, D D PierrozAbstract:The following Consensus Statement is endorsed by The International Menopause Society, The North American Menopause Society, The Endocrine Society, The European Menopause and Andropause Society, The Asia Pacific Menopause Federation, The International Osteoporosis Foundation and The Federation of Latin American Menopause Societies.
-
revised global consensus statement on menopausal hormone therapy
Climacteric, 2016Co-Authors: T J De Villiers, Jo Ann V Pinkerton, Janet E Hall, Cerdas S Perez, Margaret Rees, C Yang, D D PierrozAbstract:The following Consensus Statement is endorsed by The International Menopause Society, The North American Menopause Society, The Endocrine Society, The European Menopause and Andropause Society, The...
-
global consensus statement on menopausal hormone therapy
Climacteric, 2013Co-Authors: T J De Villiers, Janet E Hall, D D Pierroz, Margery Gass, Christopher J Haines, Roger A Lobo, Margaret ReesAbstract:The following Consensus Statement is endorsed by The American Society for Reproductive Medicine, The Asia Pacific Menopause Federation, The Endocrine Society, The European Menopause and Andropause Society, The International Menopause Society, The International Osteoporosis Foundation and The North American Menopause Society.
